Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
about
Chinese guidelines on the management of renal cell carcinoma (2015 edition)Prognostic Significance of Hypoxia-Inducible Factor Expression in Renal Cell Carcinoma: A PRISMA-compliant Systematic Review and Meta-AnalysisMolecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Novel immunotherapeutic strategies of gastric cancer treatmentProtein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma CellsPrinciples of nephrectomy for malignant disease.The role of arterial embolization in renal cell carcinoma.Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis.Renal cell carcinoma: diagnosis and treatment, 1994-2003.Renal cell carcinoma and interferon at the millennium.Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling.Interleukin 2 signaling is required for CD4(+) regulatory T cell function.Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4.The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma.Evolving role of pegylated interferons in metastatic renal cell carcinoma.MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer.Systemic therapy in metastatic renal cell carcinoma.Advances in immune-based therapies of renal cell carcinoma.Emerging drugs for renal cell carcinoma.Cytoreductive nephrectomy in metastatic renal cell carcinoma.Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II studyIntratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaPhase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinomaCurrent status of cytokine therapy in management of patients with metastatic renal cell carcinoma.The natural history of untreated renal masses.Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells.Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma.Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survivalTherapy to target renal cell carcinoma using 131I-labeled B7-H3 monoclonal antibodyImmunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.
P2860
Q26772206-2D44D0B3-F42E-4BF8-AF69-F9D757AA3E08Q26781470-6868234A-2A96-4689-9991-B419A94EAC44Q26825512-708DE509-2673-4090-8601-F349FBB4F845Q27011232-A5D0E428-A89A-4ECF-B03F-7B00721264A2Q28553350-663BA8FE-7AE7-45B6-A1AB-EDCA95097DF1Q30330068-831178C4-044F-4702-B3AA-37C661B4F413Q33714492-8A277459-E269-410B-A0B5-44D395E72FEBQ33881423-6F96480E-3DED-41EC-A23E-44128DCBA152Q33917562-A3A0DBB9-9AD8-4B88-94CA-28DD303A54B3Q34081741-76C0457E-BE22-42EE-AFEF-8942982FA2D1Q34242254-E7B129BC-45FC-4C7D-AD2B-ECD4B81BF2ADQ34371248-B3129715-8BE5-40AA-A635-3845D30B5714Q34418482-C5803052-4F36-4801-9066-74AE6DBF4219Q34527240-97A42B13-9F9F-4F7B-A657-77EB15FDE221Q34796840-E240EDA3-99A9-4736-887E-31674CCAE6B5Q35142327-B09DABFA-9330-447F-90A4-A9FCB8D063F9Q35142329-8C42784B-E623-4661-B9B1-EFC3CBF846E3Q35185775-BE2F54C2-93A5-4572-85D7-134DF9B1340EQ35611876-59CE46F6-FDB3-4995-9AAF-FFD49CA65182Q35795361-6BFC1DA8-EBE2-41AC-A83A-6498F367A8F8Q35851695-7919DE49-E458-467E-9EE3-7BC40198DCCDQ35987770-5614C31E-D375-4683-B920-312881659756Q36302842-F8CD8BED-E928-49E3-A469-D00C257B704CQ36573863-272AD0D4-C087-4B88-B410-45121A613230Q36621976-29908AAC-B0C0-4ED3-B653-F56F4823A012Q36645866-42AF677B-D2A0-4648-8F10-80D61B22503AQ36694752-04F43966-236E-4EA5-A979-03593344FFD0Q36695898-EBF71598-A86F-455D-B4BF-6C09744F0E4EQ36710382-93981318-F49B-4989-8B56-DCD0F192498AQ36794748-091AF619-6ACA-4A5F-85CC-496AEE98F4D2Q36896100-4C08B30B-0E4E-4209-8916-25083C14C3E6Q37109737-9995EB08-7237-44B9-B500-E2D73FB8E429Q37146695-A86B94C8-A06B-44C6-8465-C88DB29B32AAQ37153399-CD92AA68-781D-47F3-B7EA-2BE057D4F674Q37222476-52E87C32-3B9D-4119-9DB6-D24E6C751C94Q37269482-0474EF4F-07A3-48D5-AA56-DC4B654932E1Q37340399-447CC4CF-D31F-4725-9F3B-BCB98B177692Q37418249-518E2437-A87A-4F1A-BA1F-E474B3373F66Q37481890-995EEB45-3F93-4B54-A14A-AF8204D137FEQ37640802-AF657132-EB23-4863-A634-EDC80432D3FD
P2860
Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Natural history and therapy of ...... ma: the role of interleukin-2.
@en
type
label
Natural history and therapy of ...... ma: the role of interleukin-2.
@en
prefLabel
Natural history and therapy of ...... ma: the role of interleukin-2.
@en
P2860
P1433
P1476
Natural history and therapy of ...... ma: the role of interleukin-2.
@en
P2093
R M Bukowski
P2860
P304
P356
10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H
P407
P577
1997-10-01T00:00:00Z